Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.
She was diagnosed with the aggressive cancer of the bone marrow May 2022. This ride of her life recently led Dieks to being ...
For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...
Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant ...
A new editorial was published in Oncoscience's Volume 12 on January 14, 2025, titled "Pomalidomide improved immune profiles in myeloma." ...
Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...
Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.Continued ...
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line ...
A new editorial was published in Oncoscience’s Volume 12 on January 14, 2025, titled “Pomalidomide improved immune profiles ...
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
David Mitchell, a cancer patient and founder of Patients for Affordable Drugs, holds up a bottle of the drug Pomalyst which ...